• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.

作者信息

Fitzgerald Timothy, Zhdanava Maryia, Pilon Dominic, Shah Aditi, Lefebvre Patrick, Feldman Steven R

机构信息

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Groupe d'analyse, Montreal, QC, Canada.

出版信息

Dermatol Ther (Heidelb). 2023 Nov;13(11):2917-2923. doi: 10.1007/s13555-023-01017-8. Epub 2023 Sep 26.

DOI:10.1007/s13555-023-01017-8
PMID:37752408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10613165/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf1c/10613165/dd35c1dcee8d/13555_2023_1017_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf1c/10613165/f32ca5af60cb/13555_2023_1017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf1c/10613165/dd35c1dcee8d/13555_2023_1017_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf1c/10613165/f32ca5af60cb/13555_2023_1017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf1c/10613165/dd35c1dcee8d/13555_2023_1017_Fig2_HTML.jpg

相似文献

1
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.对编辑来信的回复：在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制
Dermatol Ther (Heidelb). 2023 Nov;13(11):2917-2923. doi: 10.1007/s13555-023-01017-8. Epub 2023 Sep 26.
2
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制。
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. doi: 10.1007/s13555-023-00910-6. Epub 2023 Mar 16.
3
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.药物生存与 Guselkumab、Ixekizumab、Secukinumab、Ustekinumab 和 Adalimumab 在银屑病患者中的治疗有效性和安全性相关。
JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909.
4
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.在中国，与司库奇尤单抗、苏金单抗、古塞库单抗和阿达木单抗用于治疗斑块状银屑病的实际应用相关的药物生存结局：一项为期52周的单中心回顾性研究。
Clin Cosmet Investig Dermatol. 2022 Oct 20;15:2245-2252. doi: 10.2147/CCID.S387759. eCollection 2022.
5
Comparative analysis of persistence and remission with guselkumab secukinumab and ixekizumab in the United States.在美国，古塞库单抗、司库奇尤单抗和依奇珠单抗的持久性和缓解率的比较分析。
J Dermatolog Treat. 2024 Dec;35(1):2349658. doi: 10.1080/09546634.2024.2349658. Epub 2024 May 15.
6
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.致编辑的信：对菲茨杰拉德等人的回应。在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制
Dermatol Ther (Heidelb). 2023 Nov;13(11):2911-2916. doi: 10.1007/s13555-023-01015-w. Epub 2023 Sep 26.
7
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.药物生存分析：白细胞介素（IL）-17 和 IL-23 抑制剂治疗银屑病的回顾性多国、多中心队列研究。
Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17.
8
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.司库奇尤单抗或古塞奇尤单抗治疗银屑病患者1年以上治疗模式的回顾性队列分析
Dermatol Ther (Heidelb). 2022 Mar;12(3):701-714. doi: 10.1007/s13555-022-00686-1. Epub 2022 Feb 26.
9
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.中重度银屑病患者中新生物制剂使用者的特征——利用现代化医学数据服务数据库的回顾性队列研究
Dermatol Ther (Heidelb). 2022 Mar;12(3):741-752. doi: 10.1007/s13555-022-00691-4. Epub 2022 Feb 24.
10
Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center.生物制剂（司库奇尤单抗、优特克单抗和古塞库单抗）治疗中度至重度银屑病的疗效与安全性比较：来自韩国单一中心的真实世界数据
Biomedicines. 2022 May 3;10(5):1058. doi: 10.3390/biomedicines10051058.

引用本文的文献

1
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab.在接受乌司奴单抗或阿达木单抗治疗的初治或经治溃疡性结肠炎患者中，真实世界的治疗持续性。
Adv Ther. 2024 Oct;41(10):3868-3887. doi: 10.1007/s12325-024-02942-6. Epub 2024 Aug 14.

本文引用的文献

1
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.致编辑的信：对菲茨杰拉德等人的回应。在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制
Dermatol Ther (Heidelb). 2023 Nov;13(11):2911-2916. doi: 10.1007/s13555-023-01015-w. Epub 2023 Sep 26.
2
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制。
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. doi: 10.1007/s13555-023-00910-6. Epub 2023 Mar 16.
3
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals.
在具有长维护间隔的生物制剂的药房索赔数据库中报告的天数供应量值存在不一致。
J Manag Care Spec Pharm. 2023 Jan;29(1):90-100. doi: 10.18553/jmcp.2023.29.1.90.
4
Navigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy.专科药房用药依从性报告的乱象。
J Manag Care Spec Pharm. 2019 Oct;25(10):1073-1077. doi: 10.18553/jmcp.2019.25.10.1073.